Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raphael Chiron

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|March 24, 2020
Effect of one-year lumacaftor-ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patientsBastien Misgault, Eva Chatron, Quitterie Reynaud, et al.
Journal of Clinical Medicine|November 13, 2020
First Wave of COVID-19 in French Patients with Cystic FibrosisHarriet Corvol, Sandra de Miranda, Lydie Lemonnier, et al.
Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology|March 23, 2024
COBRAPed cohort: Do sensitization patterns differentiate children with severe asthma from those with a milder disease?Stéphanie Lejeune, Naïm Bouazza, Pascale Roland Nicaise, et al.
Open Forum Infectious Diseases|October 21, 2022
Amikacin Liposomal Inhalation Suspension in the Treatment of <i>Mycobacterium abscessus</i> Lung Infection: A French Observational ExperienceRaphael Chiron, Wouter Hoefsloot, Jakko Van Ingen, et al.
Medical Microbiology and Immunology|October 27, 2014
A French multicentric study and review of pulmonary Nocardia spp. in cystic fibrosis patientsVerónica Rodriguez-Nava, Stéphane Durupt, Sandra Chyderiotis, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 27, 2025
Cannabinoid receptor 2 agonist, lenabasum, for the treatment of pulmonary exacerbations in cystic fibrosisNatalie E West, Michael W Konstan, Patrick A Flume, et al.
The Lancet. Respiratory Medicine|September 6, 2025
Sweat chloride and lung function responses to elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with two versus one responsive CFTR variants: an analysis of two real-world observational studiesPierre-Régis Burgel, Jennifer Da Silva, Emmanuelle Girodon, et al.
Clinical and Translational Science|May 10, 2025
Elexacaftor/Tezacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients With Cystic FibrosisNgoc Hoa Truong, Sihem Benaboud, Naïm Bouazza, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|July 8, 2023
Nonsense mutations accelerate lung disease and decrease survival of cystic fibrosis childrenAnnalisa Orenti, Iwona Pranke, Caroline Faucon, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|August 10, 2014
Central venous thrombosis and thrombophilia in cystic fibrosis: A prospective studyAnne Munck, Ahmed Kheniche, Corinne Alberti, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|March 24, 2020
Effect of one-year lumacaftor-ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patientsBastien Misgault, Eva Chatron, Quitterie Reynaud, et al.
Journal of Clinical Medicine|November 13, 2020
First Wave of COVID-19 in French Patients with Cystic FibrosisHarriet Corvol, Sandra de Miranda, Lydie Lemonnier, et al.
Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology|March 23, 2024
COBRAPed cohort: Do sensitization patterns differentiate children with severe asthma from those with a milder disease?Stéphanie Lejeune, Naïm Bouazza, Pascale Roland Nicaise, et al.
Open Forum Infectious Diseases|October 21, 2022
Amikacin Liposomal Inhalation Suspension in the Treatment of <i>Mycobacterium abscessus</i> Lung Infection: A French Observational ExperienceRaphael Chiron, Wouter Hoefsloot, Jakko Van Ingen, et al.
Medical Microbiology and Immunology|October 27, 2014
A French multicentric study and review of pulmonary Nocardia spp. in cystic fibrosis patientsVerónica Rodriguez-Nava, Stéphane Durupt, Sandra Chyderiotis, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 27, 2025
Cannabinoid receptor 2 agonist, lenabasum, for the treatment of pulmonary exacerbations in cystic fibrosisNatalie E West, Michael W Konstan, Patrick A Flume, et al.
The Lancet. Respiratory Medicine|September 6, 2025
Sweat chloride and lung function responses to elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with two versus one responsive CFTR variants: an analysis of two real-world observational studiesPierre-Régis Burgel, Jennifer Da Silva, Emmanuelle Girodon, et al.
Clinical and Translational Science|May 10, 2025
Elexacaftor/Tezacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients With Cystic FibrosisNgoc Hoa Truong, Sihem Benaboud, Naïm Bouazza, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|July 8, 2023
Nonsense mutations accelerate lung disease and decrease survival of cystic fibrosis childrenAnnalisa Orenti, Iwona Pranke, Caroline Faucon, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|August 10, 2014
Central venous thrombosis and thrombophilia in cystic fibrosis: A prospective studyAnne Munck, Ahmed Kheniche, Corinne Alberti, et al.
Pageof 4